Floatz logo

Venetoclax

Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent

Princess Maxima Center for Pediatric OncologySmall moleculePhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

48 Active assets in the Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Princess Maxima Center for Pediatric Oncology
Phase 3BB
PREDNISONE TABLETS
Children's Oncology Group
Phase 3BB
Cyclophosphamide
Children's Oncology Group
Phase 3BB
ETOPOSIDE
Children's Cancer Group, China
Phase 3BB
VINCRISTINE SULFATE
Children's Oncology Group
Phase 2/3B

View all 50 →

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →